Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel.
Saved in:
| Title: | Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel. |
|---|---|
| Authors: | Droz JP; aDepartment of Medical Oncology, Centre Léon-Bérard, Claude Bernard Lyon-1 University, Lyon bMedical Oncology Department, Georges Pompidou European Hospital (HEGP), Paris cDepartment of Medical Oncology, Institut Claudius Regaud, Toulouse dBoehringer Ingelheim France S.A.S, Reims, France eBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Medioni J, Chevreau C, De Mont-Serrat H, Merger M, Stopfer P, Kaiser R, Oudard S |
| Source: | Anti-cancer drugs [Anticancer Drugs] 2014 Oct; Vol. 25 (9), pp. 1081-8. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1473-5741 |
|---|---|
| DOI: | 10.1097/CAD.0000000000000131 |
